Implementation of hypofractionated prostate radiation therapy in the United States: A National Cancer Database analysis

Practical Radiation Oncology

Volumn 7, Issue 4, 2017, Pages 270-278

  Stokes, William A ^a   Kavanagh, Brian D ^a   Raben, David ^a   Pugh, Thomas J ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; DATA BASE; EXTERNAL BEAM RADIOTHERAPY; HEALTH CARE FACILITY; HEALTH INSURANCE; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; INCOME; LAND USE; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; RADIATION DOSE; TREND STUDY; TUMOR LOCALIZATION; UNITED STATES; NATIONAL HEALTH ORGANIZATION; PATHOLOGY; PROSTATE TUMOR; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DOSE HYPOFRACTIONATION; HUMANS; MALE; MIDDLE AGED; NATIONAL CANCER INSTITUTE (U.S.); PROSTATIC NEOPLASMS; TREATMENT OUTCOME; UNITED STATES;

EID: 85021665260     PISSN: 18798500     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prro.2017.03.011     Document Type: Article

References (45)

1. Mohler, JL, Armstrong, AJ, Bahnson, RR, et al. Prostate cancer, version 1.2016. J Natl Compr Cancer Netw 14 (2016), 19–30.
2. Zietman, A, Moughan, J, Owen, J, Hanks, G, The patterns of care survey of radiation therapy in localized prostate cancer: Similarities between the practice nationally and in minority-rich areas. Int J Radiat Oncol Biol Phys 50 (2001), 75–80.
3. Deore, SM, Shrivastava, SK, Supe, SJ, Viswanathan, PS, Dinshaw, KA, Alpha/beta value and importance of dose per fraction for the late rectal and recto-sigmoid complications. Strahlenther Onkol 169 (1993), 521–526.
4. Haustermans, KM, Hofland, I, Van Poppel, H, et al. Cell kinetic measurements in prostate cancer. Int J Radiat Oncol Biol Phys 37 (1997), 1067–1070.
5. Brenner, DJ, Martinez, AA, Edmundson, GK, Mitchell, C, Thames, HD, Armour, EP, Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52 (2002), 6–13.
6. Kupelian, PA, Willoughby, TR, Reddy, CA, Klein, EA, Mahadevan, A, Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 gy per fraction) for localized prostate cancer: Cleveland clinic experience. Int J Radiat Oncol Biol Phys 68 (2007), 1424–1430.
7. McCammon, R, Rusthoven, KE, Kavanagh, B, Newell, S, Newman, F, Raben, D, Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer. Int J Radiat Oncol Biol Phys 75 (2009), 413–420.
8. Lee, WR, Dignam, JJ, Amin, MB, et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol, 2016 JCO670448.
9. Catton, CN, Lukka, H, Gu, CS, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. [e-pub ahead of print] J Clin Oncol, 2017, 10.1200/JCO.2016.71.7397 accessed April 12, 2017.
10. Dearnaley, D, Syndikus, I, Mossop, H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHIP trial. Lancet Oncol 17 (2016), 1047–1060.
11. King, CR, Freeman, D, Kaplan, I, et al. Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol 109 (2013), 217–221.
12. King, CR, Collins, S, Fuller, D, et al. Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: Results from a multi-institutional consortium of prospective trials. Int J Radiat Oncol Biol Phys 87 (2013), 939–945.
13. De Bari, B, Arcangeli, S, Ciardo, D, et al. Extreme hypofractionation for early prostate cancer: Biology meets technology. Cancer Treat Rev 50 (2016), 48–60.
14. Lee, WR, Hypofractionation for prostate cancer: Tested and proven. Lancet Oncol 17 (2016), 1020–1022.
15. Lukka, H, Hayter, C, Julian, JA, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 23 (2005), 6132–6138.
16. Madsen, BL, Hsi, RA, Pham, HT, Fowler, JF, Esagui, L, Corman, J, Stereotactic Hypofractionated Accurate Radiotherapy of the Prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results. Int J Radiat Oncol Biol Phys 67 (2007), 1099–1105.
17. Tang, C, Loblaw, D, Cheung, P, et al. Phase I/II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localised prostate cancer: Early results of PHART3. Clin Oncol 20 (2008), 729–737.
18. King, CR, Brooks, JD, Gill, H, Pawlicki, T, Cotrutz, C, Presti, JC Jr., Stereotactic body radiotherapy for localized prostate cancer: Interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 73 (2009), 1043–1048.
19. Fuller, DB, Mardirossian, G, Wong, D, McKellar, H, Prospective evaluation of stereotactic radiotherapy for low and intermediate risk prostate cancer: Emulating HDR brachytherapy dose distribution. Int J Radiat Oncol Biol Phys 78 (2010), S358–S359.
20. Boike, TP, Lotan, Y, Cho, LC, et al. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol 29 (2011), 2020–2026.
21. Meier, R, Kaplan, I, Beckman, A, et al. Stereotactic body radiation therapy for intermediate-risk organ-confined prostate cancer: Interim toxicity and quality of life outcomes from a multi-institutional study. Int J Radiat Oncol Biol Phys, 84, 2012, S148.
22. Zeliadt, SB, Potosky, AL, Etzioni, R, Ramsey, SD, Penson, DF, Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology 64 (2004), 1171–1176.
23. Gross, CP, Smith, BD, Wolf, E, Andersen, M, Racial disparities in cancer therapy: Did the gap narrow between 1992 and 2002?. Cancer 112 (2008), 900–908.
24. Moses, KA, Paciorek, AT, Penson, DF, Carroll, PR, Master, VA, Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: Data from CaPSURE. J Clin Oncol 28 (2010), 1069–1074.
25. Stokes, WA, Hendrix, LH, Royce, TJ, et al. Racial differences in time from prostate cancer diagnosis to treatment initiation: A population-based study. Cancer 119 (2013), 2486–2493.
26. Yeoh, EE, Botten, RJ, Butters, J, Di Matteo, AC, Holloway, RH, Fowler, J, Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: Final results of phase III randomized trial. Int J Radiat Oncol Biol Phys 81 (2011), 1271–1278.
27. Pollack, A, Walker, G, Horwitz, EM, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 1 (2013), 3860–3868.
28. Hoffman, KE, Voong, KR, Pugh, TJ, et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: Results from a randomized trial. Int J Radiat Oncol Biol Phys 88 (2014), 1074–1084.
29. Arcangeli, S, Strigari, L, Gomellini, S, et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 84 (2012), 1172–1178.
30. Incrocci, L, Wortel, RC, Alemayehu, WG, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): Final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 17 (2016), 1061–1069.
31. King, CR, Brooks, JD, Gill, H, Presti, JC, Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 82 (2012), 877–882.
32. Aluwini, S, Beltramo, G, Van Rooij, P, Boormans, J, Kirkels, W, Kolkman-Deurloo, I-K, P068 stereotactic body radiotherapy with four fractions for low-and intermediate-risk prostate cancer: Acute and late toxicity. Eur Urol Suppl, 6, 2013, 156.
33. Chen, LN, Suy, S, Uhm, S, et al. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: The Georgetown University experience. Radiat Oncol, 8, 2013, 1.
34. D'Alimonte, L, Loblaw, A, Cheung, P, et al. Long term outcomes of a novel five fraction hypofractionated protocol for low risk prostate cancer. J Med Imaging Radiat Sci, 44, 2013, 47.
35. Bolzicco, G, Favretto, MS, Satariano, N, Scremin, E, Tambone, C, Tasca, A, A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy. BMC Urol, 13, 2013, 49.
36. Katz, A, Kang, J, Stereotactic body radiation therapy for low-, intermediate-, and high-risk prostate cancer: Disease control and quality of life at 6 years. Int J Radiat Oncol Biol Phys 87 (2013), S24–S25.
37. Loblaw, A, Cheung, P, D'Alimonte, L, et al. Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: Toxicity, biochemical, and pathological outcomes. Radiother Oncol 107 (2013), 153–158.
38. Lukka, H, Stephanie, P, Bruner, D, et al. Patient-reported outcomes in NRG Oncology/RTOG 0938, a randomized phase 2 study evaluating 2 ultrahypofractionated regimens (UHRs) for prostate cancer. Int J Radiat Oncol Biol Phys, 94, 2016, 2.
39. Widmark, A, Gunnlaugsson, A, Beckman, L, et al. Extreme hypofractionation versus conventionally fractionated radiotherapy for intermediate risk prostate cancer: Early toxicity results from the Scandinavian randomized phase III trial “HYPO-RT-PC”. Int J Radiat Oncol Biol Phys 96 (2016), 938–939.
40. Madsen, BL, Hsi, RA, Pham, HT, et al. Intrafractional stability of the prostate using a stereotactic radiotherapy technique. Int J Radiat Oncol Biol Phys 57 (2003), 1285–1291.
41. King, CR, Lehmann, J, Adler, JR, Hai, J, CyberKnife radiotherapy for localized prostate cancer: Rationale and technical feasibility. Technol Cancer Res Treat 2 (2003), 25–30.
42. Baker, BR, Basak, R, Mohiuddin, JJ, Chen, RC, Use of stereotactic body radiotherapy for prostate cancer in the United States from 2004 through 2012. Cancer 122 (2016), 2234–2241.
43. Wang, EH, Mougalian, SS, Soulos, PR, et al. Adoption of hypofractionated whole-breast irradiation for early-stage breast cancer: A National Cancer Data Base analysis. Int J Radiat Oncol Biol Phys 90 (2014), 993–1000.
44. Jagsi, R, Falchook, AD, Hendrix, LH, Curry, H, Chen, RC, Adoption of hypofractionated radiation therapy for breast cancer after publication of randomized trials. Int J Radiat Oncol Biol Phys 90 (2014), 1001–1009.
45. Rutter, CE, James, BY, Wilson, LD, Park, HS, Assessment of national practice for palliative radiation therapy for bone metastases suggests marked underutilization of single-fraction regimens in the United States. Int J Radiat Oncol Biol Phys 91 (2015), 548–555.